Skip to content

Study · In vitro (cells) · 2004

1 result

The role of the acid-labile subunit in regulating insulin-like growth factor transport across human umbilical vein endothelial cell monolayers.

Payet LD, Firth SM, Baxter RC

The Journal of clinical endocrinology and metabolism1 May 2004Cited by 19 (Europe PMC)

PMID15126567 (opens in a new tab)DOI10.1210/jc.2003-031880 (opens in a new tab)PepBankPUB-15126567
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Pharmacokinetics

    In human endothelial monolayers, transport of radiolabeled des(1‑3)IGF-I was faster than transport of radiolabeled IGF-I.

    In plain wordsIn cells, labeled des(1‑3)IGF-I crossed human blood vessel cell layers faster than labeled IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseTransendothelial transport rate
    Study

    humann: not reported in source

    Human umbilical vein endothelial cell monolayers
    Comparator
    (125)I-IGF-I
    Outcome group
    Pharmacokinetics · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Transport of (125)I-des(1-3)IGF-I was more rapid than (125)I-IGF-I, suggesting the presence of some endogenous IGFBPs, although these were undetectable by affinity labeling of cells or medium.
    1 context sentence
    Summary · context
    We have established a human umbilical vein endothelial cell (HUVEC) monolayer system to study the role of complex formation with IGF binding protein (IGFBP) and acid-labile subunit (ALS) on the transendothelial transport of IGF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.